187 related articles for article (PubMed ID: 15190520)
21. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
22. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2014 Sep; 89(9):915-25. PubMed ID: 25124313
[TBL] [Abstract][Full Text] [Related]
23. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis.
Anderson JE; Sale G; Appelbaum FR; Chauncey TR; Storb R
Br J Haematol; 1997 Sep; 98(4):1010-6. PubMed ID: 9326205
[TBL] [Abstract][Full Text] [Related]
24. [Use of interferon in the treatment of chronic myeloproliferative disorders].
Robak T
Acta Haematol Pol; 1992; 23(2 Suppl 1):30-7. PubMed ID: 1488870
[TBL] [Abstract][Full Text] [Related]
25. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
[TBL] [Abstract][Full Text] [Related]
26. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia.
Kerbauy DM; Gooley TA; Sale GE; Flowers ME; Doney KC; Georges GE; Greene JE; Linenberger M; Petersdorf E; Sandmaier BM; Scott BL; Sorror M; Stirewalt DL; Stewart FM; Witherspoon RP; Storb R; Appelbaum FR; Deeg HJ
Biol Blood Marrow Transplant; 2007 Mar; 13(3):355-65. PubMed ID: 17317589
[TBL] [Abstract][Full Text] [Related]
27. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation.
Ciurea SO; Sadegi B; Wilbur A; Alagiozian-Angelova V; Gaitonde S; Dobogai LC; Akard LP; Hoffman R; Rondelli D
Br J Haematol; 2008 Apr; 141(1):80-3. PubMed ID: 18324970
[TBL] [Abstract][Full Text] [Related]
28. Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options.
Mesa RA; Barosi G; Cervantes F; Reilly JT; Tefferi A
Best Pract Res Clin Haematol; 2006; 19(3):495-517. PubMed ID: 16781486
[TBL] [Abstract][Full Text] [Related]
29. Unrelated stem cell transplant for infantile idiopathic myelofibrosis.
Domm J; Calder C; Manes B; Crossno C; Correa H; Frangoul H
Pediatr Blood Cancer; 2009 Jul; 52(7):893-5. PubMed ID: 19241452
[TBL] [Abstract][Full Text] [Related]
30. Inflammation and myeloproliferative neoplasms.
Lussana F; Rambaldi A
J Autoimmun; 2017 Dec; 85():58-63. PubMed ID: 28669446
[TBL] [Abstract][Full Text] [Related]
31. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
32. [Clinico-hematological characteristics of acute transformation of chronic myeloproliferative syndromes].
Hernández JM; San Miguel JF; González M; Moraleda JM; Moro MJ; Hernández J; Cuesta B; López Borrasca A
Med Clin (Barc); 1991 Sep; 97(10):369-72. PubMed ID: 1745085
[TBL] [Abstract][Full Text] [Related]
33. The therapy of myelofibrosis: targeting pathogenesis.
Mesa RA
Int J Hematol; 2002 Aug; 76 Suppl 2():296-304. PubMed ID: 12430941
[TBL] [Abstract][Full Text] [Related]
34. Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden.
Mesa RA; Passamonti F
Am Soc Clin Oncol Educ Book; 2016; 35():e324-35. PubMed ID: 27249739
[TBL] [Abstract][Full Text] [Related]
35. [Allogeneic hematopoietic stem cell transplantation for myeloproliferative neoplasms].
Takenaka K
Rinsho Ketsueki; 2019; 60(9):1148-1156. PubMed ID: 31597838
[TBL] [Abstract][Full Text] [Related]
36. Plasma basic fibroblast growth factor and bone marrow fibrosis in clonal myeloproliferative disorders.
Sayinalp N; Cinar H; Uner A; Haznedaroğlu IC; Büyükaşik Y; Göker H; Aksu S; Ozcebe OI; Karakuş S; Kirazli S; Dündar SV
Clin Lab Haematol; 2004 Aug; 26(4):265-8. PubMed ID: 15279663
[TBL] [Abstract][Full Text] [Related]
37. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management.
Tefferi A
Am J Hematol; 2018 Dec; 93(12):1551-1560. PubMed ID: 30039550
[TBL] [Abstract][Full Text] [Related]
38. Hematopoietic cell transplantation for chronic myeloproliferative disorders.
Tse W; Deeg HJ
Arch Immunol Ther Exp (Warsz); 2006; 54(6):375-80. PubMed ID: 17122883
[TBL] [Abstract][Full Text] [Related]
39. Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis.
Rosti V; Campanelli R; Massa M; Viarengo G; Villani L; Poletto V; Bonetti E; Catarsi P; Magrini U; Grolla AA; Travelli C; Genazzani AA; Barosi G
Am J Hematol; 2016 Jul; 91(7):709-13. PubMed ID: 27074203
[TBL] [Abstract][Full Text] [Related]
40. Idiopathic myelofibrosis: historical review, diagnosis and management.
Weinstein IM
Blood Rev; 1991 Jun; 5(2):98-104. PubMed ID: 1912760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]